Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystal form of fulvestrant and preparation method thereof

A fulvestrant and crystal form technology, which is applied in the direction of medical preparations containing active ingredients, pharmaceutical formulas, steroids, etc., can solve the problem of no mention of crystal form spectral characteristics, no literature mention of fulvestrant Problems such as crystal form and preparation method have been solved to achieve the effect of good bulk density, stable crystal form and no decrease in content

Active Publication Date: 2009-09-09
HANGZHOU JIUYUAN GENE ENG +1
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, so far, no literature has mentioned the crystal form and preparation method of fulvestrant, let alone the spectral characteristics of the relevant crystal form

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal form of fulvestrant and preparation method thereof
  • Crystal form of fulvestrant and preparation method thereof
  • Crystal form of fulvestrant and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The preparation of embodiment 1 fulvestrant intermediate II

[0035] Add 10g bromide (Br-(CH 2 ) 9 -S-(CH 2 ) 3 -CF 2 CF 3 , see scheme 2), 0.7g metal magnesium and 100ml dry tetrahydrofuran, the mixture was heated to 77°C for 3h, cooled to room temperature, and used under the protection of nitrogen. This makes the Grignard reagent.

[0036] In another reaction flask, add 5g of 6-dehydronandrolone acetate, 50ml of dry tetrahydrofuran, and 0.5g of anhydrous ketone acetate, cool the reaction mixture to -45°C ~ -50°C, and slowly add the above Grignard reagent, add dropwise within 3.5h, react at -45°C for 4h after addition, end the mixture with 5ml of concentrated hydrochloric acid, keep the temperature below 10°C, keep the mixture below 10°C for 30 minutes, during about 20 minutes , add 50ml of water, add 100ml of dichloromethane, separate the water layer, wash the dichloromethane layer with 10ml of 25% ammonia water, and finally wash the dichloromethane with water ...

Embodiment 2

[0037] The preparation of embodiment 2 fulvestrant intermediate III

[0038]Add 4g of Intermediate II, 50ml of anhydrous methanol and 1g of potassium hydroxide to the reaction flask, stir and react at 20°C to 30°C for 24h, evaporate the methanol to dryness in a water bath below 30°C, add 10ml of water and 100ml of acetic acid to the residue Ethyl was mixed, then 1ml of acetic acid was added to adjust the pH to 6, the aqueous layer was separated, the ethyl acetate layer was washed with water until neutral, dried over anhydrous sodium sulfate, and the ethyl acetate was evaporated to dryness to obtain 3.1g of an oil (intermediate III), which was directly used in the next step.

Embodiment 3

[0039] Embodiment 3 Preparation of Fulvestrant Intermediate IV

[0040] Add 6g of intermediate III, 80ml of dry acetonitrile, 5.3g of copper bromide, and 1.1g of lithium bromide into the reaction flask, and heat the mixture to reflux for 3h. After the reaction is completed, the mixture is cooled to room temperature, and stirred by adding 6g of 25% ammonia water and 50ml of dichloromethane After 12 hours, the water layer was separated, the dichloromethane layer was washed with water until neutral, and the dichloromethane was evaporated to dryness to obtain 5.8 g of an oil (intermediate IV).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel crystal form of fulvestrant, a preparation method thereof and a pharmaceutical composition containing the crystal form.

Description

technical field [0001] The present invention relates to new crystal forms of fulvestrant, its preparation method and pharmaceutical compositions containing these crystal forms. Background of the invention [0002] The chemical name of fulvestrant is: (7a, 17b)-7-[9-(4,4,5,5,5-pentafluoropentasulfinyl)nonyl]-estra-1,3, 5-(10)-triene-3,17-diol, molecular formula C 32 h 47 f 5 o 3 S, the molecular weight is 606.77, and its structural formula is as follows: [0003] [0004] Fulvestrant (Fulvestrant) was first successfully developed by AstraZeneca, and was approved by the US FDA in 2002. The trade name is Faslodex. For the treatment of postmenopausal metastatic advanced breast cancer, intramuscular injection once a month, 250mg each time, can be injected as a single injection (5ml once) or divided into 2 injections (2.5ml once). [0005] Fulvestrant is a new class of estrogen receptor (ER) inhibitor-ER downregulator drugs for the treatment of breast cancer. Since ER is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07J1/00A61K31/56A61P35/00
Inventor 李勇王沿江郑力徐飞虎孙汉栋
Owner HANGZHOU JIUYUAN GENE ENG